{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-052295","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2025-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.433666+00:00","generated_at":"2026-05-19T17:18:23.283842+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Hoth Therapeutics updates pipeline timelines, reports cash runway and share count in corporate deck","bullets":["Cash on hand sufficient to fund all clinical and preclinical programs in development.","13.2 million shares outstanding as of June 6, 2025; no outstanding debt noted.","HT-001 Phase 2a open-label PK data expected Q1 2025; full dataset Q4 2025.","HT-KIT IND submission targeted Q1 2026; GLP tox & GMP API manufacturing initiated Q1 2025.","HT-ALZ pre-IND meeting submission planned for 2025; 505(b)(2) pathway pursued."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-052295","json":"https://secwatch.observer/filing/0001213900-25-052295.json","markdown":"https://secwatch.observer/filing/0001213900-25-052295.md","text":"https://secwatch.observer/filing/0001213900-25-052295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025052295/0001213900-25-052295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025052295/ea0245073-8k_hoth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T17:18:23.283842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}